2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

HepG2 cancer cells

" in MedChemExpress (MCE) Product Catalog:

197

Inhibitors & Agonists

4

Fluorescent Dyes

4

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

54

Natural
Products

3

Isotope-Labeled Compounds

2

Click Chemistry

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0069
    Solamargine
    Maximum Cited Publications
    12 Publications Verification

    Solamargin; δ-Solanigrine

    		 P-glycoprotein Apoptosis Cancer
    Solamargine, a derivative from the steroidal solasodine in Solanum species, exhibits anticancer activities in numerous types of cancer. Solamargine induces non-selective cytotoxicity and P-glycoprotein inhibition. Solamargine significantly inhibits migration and invasion of HepG2 cells by down-regulating MMP-2 and MMP-9 expression and activity .
    Solamargine
  • HY-N0316
    Mollugin
    2 Publications Verification

    		 JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
    Mollugin
  • HY-N0396
    Harpagoside
    4 Publications Verification

    		 COX NO Synthase Inflammation/Immunology Cancer
    Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ).
    Harpagoside
  • HY-N2078
    Yamogenin

    Neodiosgenin

    		 LXR Reactive Oxygen Species (ROS) Apoptosis Fatty Acid Synthase (FASN) Metabolic Disease
    Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes. Yamogenin is a steroidal saponin that can be obtained from plant species with in vitro cytotoxicity, antioxidant, and antimicrobial properties. Yamogenin induces cell death via the extrinsic and intrinsic way of apoptosis. Yamogenin inhibits protein denaturation with an IC50 of 1421.92 μg/mL. Yamogenin can be studied in research on gastric cancer .
    Yamogenin
  • HY-165422
    ALKBH5-IN-3

    		Anaplastic lymphoma kinase (ALK) Cancer
    ALKBH5-IN-3 is a selective, cell active ALKBH5 inhibitor with an IC50 of 0.021 μM. ALKBH5-IN-3 stabilizes ALKBH5 in HepG2 cells, and increases m 6A level in intact cells. ALKBH5-IN-3 can be used as a versatile chemical probe to explore the biological function of ALKBH5. ALKBH5-IN-3 can be used for the research of Cancer .
    ALKBH5-IN-3
  • HY-113064
    Selenocystine
    1 Publications Verification

    		 Endogenous Metabolite Cancer
    Selenocystine is a broad-spectrum anti-cancer agent. Selenocystine induces DNA damage in HepG2 cells, particularly in the form of DNA double strand breaks (DSBs). Selenocystine exhibits great promise as a therapeutic or adjuvant agent targeting DNA repair for cancer treatment .
    Selenocystine
  • HY-N5052
    Asiaticoside B

    		Others Cancer
    Asiaticoside B is a 9,19-cycloartane triterpene glycoside found in Actaea asiatica. Asiaticoside B has cytotoxicity against HepG2 and MCF-7 cancer cells with IC50 values of 9.74 µM and 8.32 µM, respectively .
    Asiaticoside B
  • HY-D2315
    Probe-Cys

    		Fluorescent Dye Cancer
    Probe-Cys is a water-soluble and selective near-infrared fluorescent probe for Cysteine (Cys) (λex= 680 nm, λem=710 nm) that is not interfered by Hcy, GSH, and HS-. Probe-Cys can react with the stimulant DTT (HY-15917) and the NEM (HY-D0843) in HepG2 cells and zebrafish for the detection of endogenous Cys. Probe-Cys can also be used for imaging Cys in Arabidopsis thaliana. Probe-Cys provides a method for cancer diagnosis and exploration of plant sulfur metabolism .
    Probe-Cys
  • HY-N7160
    2-Hydroxy-3-methylanthraquinone

    		Src Apoptosis Cancer
    2-Hydroxy-3-methylanthraquinone (compound 1) is a natural compound isolated from a water extract of Hedyotis diffusa WILLD. 2-Hydroxy-3-methylanthraquinone shows inhibitory activity against protein tyrosine kinases v-src and pp60src, and induces growth arrest and apoptosis in the HepG2 cancer cells .
    2-Hydroxy-3-methylanthraquinone
  • HY-151486
    GLUT1-IN-1

    		GLUT Cancer
    GLUT1-IN-1 is a glucose transporter 1 (GLUT1) inhibitor and has a GLUT1-specific inactivation ability. GLUT1-IN-1 exhibits concentration-dependent cytotoxicity for HeLa, A549 and HepG2 cells with IC50 values of 5.49 μM, 11.14 μM, and 8.73 μM, respectively. GLUT1-IN-1 can be used for the research of photodynamic therapy (PDT) and severals cancer .
    GLUT1-IN-1
  • HY-177291
    LAB687

    		Microsomal Triglyceride Transfer Protein (MTP) Smo Hedgehog LDLR Cardiovascular Disease Cancer
    LAB687 is a microsomal triglyceride transfer protein (MTP) inhibitor with an IC50 of 0.9 nM for apolipoprotein B (apoB) secretion in HepG2 cells. LAB687 also acts as a Smoothened (Smo) antagonist, with IC50 values of 2.48 μM and 3.42 μM against mouse and human Smo receptors, respectively. LAB687 reduces triglyceride and low-density lipoprotein cholesterol (LDL-C) levels, and inhibits the Hedgehog signaling pathway. LAB687 can be used in studies related to Hedgehog-dependent cancers .
    LAB687
  • HY-175208
    MST3-IN-1

    		Hippo (MST) Caspase Bcl-2 Family Apoptosis Cancer
    MST3-IN-1 is a selective and orally active MST3 inhibitor, with an IC50 of 122.4 nM. MST3-IN-1 shows antiproliferative activity against HepG2 cell. MST3-IN-1 effectively induces apoptosis in HepG2 cells, and halts the cell cycle at the G2/M transition. MST3-IN-1 significantly suppressed tumor growth in HepG2 xenograft mice. MST3-IN-1 can be used for the study of liver cancer .
    MST3-IN-1
  • HY-P1935
    Cyclo(Ala-​Pro)

    		Biochemical Assay Reagents Cancer
    Cyclo(Ala-Pro) is an anticancer agent that is toxic to cancer cells such as A549, HCT-116 and HepG2 .
    Cyclo(Ala-​Pro)
  • HY-170027
    LW1564

    		HIF/HIF Prolyl-Hydroxylase AMPK Cancer
    LW1564 is an inhibitor for HIF-1α with an IC50 of 1.2 µM in HepG2. LW1564 inhibits mitochondrial respiration, reduces ATP production, stimulates HIF-1α degradation, and inhibits proliferation of various cancer cells with GI50 of 0.4-4.6 μM. LW1564 activates AMPK signaling pathway and inhibits lipid synthesis. LW1564 exhibits antitumor in HepG2 xenograft mouse model .
    LW1564
  • HY-126535
    Magnoloside B

    		Glycosidase Metabolic Disease Cancer
    Magnoloside B is an α-glucosidase inhibitor (IC50=0.69 mM), which can be obtained from Magnolia officinalis stem bark. Magnoloside B shows moderate inhibitory activity against MGC-803 and HepG2 cells. Magnoloside B has the potential to study cancer and diabetes .
    Magnoloside B
  • HY-B0144AS1
    Pitavastatin-d5 sodium

    NK-104-d5 sodium

    		 Apoptosis HMG-CoA Reductase (HMGCR) Mitophagy Autophagy Metabolic Disease Cancer
    Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
    Pitavastatin-d5 sodium
  • HY-146819
    CAIX/CAXII-IN-1

    		Carbonic Anhydrase Cancer
    Compound 9 is the most effective against tumor specific Ca ix/ca XII (ki=29.1 and 8.8 nm), so it is possible to evaluate its cytotoxicity and selectivity to HepG-2, HCT-116 and MCF-7 cancer cell lines in vitro, and its IC50 values to tumor cells are 1.78, 1.94 and 3.07, respectively μ M. It showed that it had obvious cytotoxicity.
    CAIX/CAXII-IN-1
  • HY-151573
    EGFR/CDK2-IN-1

    		EGFR CDK Cancer
    EGFR/CDK2-IN-1 (Compound 3b) is an EGFR/CDK2 inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .
    EGFR/CDK2-IN-1
  • HY-20559
    4-Chloro-3-nitrobenzoic acid

    		Drug Intermediate Cancer
    4-Chloro-3-nitrobenzoic acid is a benzoic acid derivative and an important intermediate for the synthesis of anticancer agents. 4-Chloro-3-nitrobenzoic acid shows low cytotoxicity against HepG2, A549 and HeLa cancer cells in vitro (>10,000 μM). 4-Chloro-3-nitrobenzoic acid can block thymidine uptake and inhibit lymphocyte growth. 4-Chloro-3-nitrobenzoic acid serves as a ligand for Cu (II) complexes and is used in the preparation of 10H-pyrazino[2,3-b][1,4]benzothiazine derivatives .
    4-Chloro-3-nitrobenzoic acid
  • HY-143301
    Topoisomerase I inhibitor 4

    		Topoisomerase Cancer
    Topoisomerase I inhibitor 4 (compound 7a) is a topoisomerase I inhibitor. Topoisomerase I inhibitor 4 inhibits HepG2, A549, MCF-7 and HeLa cancer cells proliferation with IC50s of 1.20, 2.09, 1.56 and 1.92 μM, respectively. Topoisomerase I inhibitor 4 can be used for the research of cancer .
    Topoisomerase I inhibitor 4
  • HY-N13772
    3'-O-Methyltaxifolin

    (+)-Dihydroisorhamnetin

    		 Apoptosis Cancer
    3'-O-Methyltaxifolin ((+)-Dihydroisorhamnetin) is a dihydroflavanol found in Pulicaria jaubertii. A mixture of these alcohol compounds including 3'-O-Methyltaxifolin found in Pulicaria jaubertii exhibits antitumor activity with IC50 values ​​of 19.1 μg, 20.0 μg, and 24.1 μg against prostate cancer (PC-3), breast cancer (MCF-7), and hepatocellular carcinoma (HepG-2) cell lines, respectively. Furthermore, 3'-O-Methyltaxifolin can induce cell apoptosis, making it a promising candidate for anticancer research. .
    3'-O-Methyltaxifolin
  • HY-151453
    Topoisomerase IIα-IN-4

    		Topoisomerase Apoptosis Cancer
    Topoisomerase IIα-IN-4 (F2) is a non-intercalative ATP-competitive human DNA topoisomerase II inhibitor with an IC50 value of 3.8 and 10.1 μM for TopoIIα and TopoIIβ, respectively. Topoisomerase IIα-IN-4 shows potent potency in apoptosis induction and cell cycle arrest in HepG2 cells. Topoisomerase IIα-IN-4 exhibits strong antitumor activities against human cancer cell lines, it can be used for the research of cancer .
    Topoisomerase IIα-IN-4
  • HY-126876
    GL-V9
    1 Publications Verification

    		 Apoptosis AMPK Reactive Oxygen Species (ROS) Cancer
    GL-V9 inhibits proliferation of HepG2 cell (IC50 is 35.2 μM) through induction of apoptosis and cell cycle arrest at G2/M phase. GL-V9 regulates mitochondrial membrane potential and increases the production of intracellular reactive oxygen species. GL-V9 inhibits the pentose phosphate pathway (PPP), enhances fatty acid oxidation (FAO) through activation of AMPK, and thus inhibits the metastasis of cancer cells. GL-V9 exhibits antitumor efficacy in mouse model .
    GL-V9
  • HY-156912
    Tyrosine kinase-IN-7

    		EGFR Cancer
    Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC50s for inhibiting EGFR(WT) and EGFR(T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC50s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively .
    Tyrosine kinase-IN-7
  • HY-175208A
    MST3-IN-1 TFA

    		Hippo (MST) Caspase Bcl-2 Family Apoptosis Cancer
    MST3-IN-1 TFA (Compound LD-1) is a selective and orally active MST3 inhibitor, with an IC50 of 122.4 nM. MST3-IN-1 TFA shows antiproliferative activity against HepG2 cell. MST3-IN-1 TFA effectively induces Apoptosis in HepG2 cells, and halts the cell cycle at the G2/M transition. MST3-IN-1 TFA significantly suppressed tumor growth in HepG2 xenograft mice. MST3-IN-1 TFA can be used for the study of liver cancer .
    MST3-IN-1 TFA
  • HY-146729
    ASK1-IN-3

    		ASK1 MAP3K Apoptosis Inflammation/Immunology Cancer
    ASK1-IN-3 is a potent and selective ASK1 kinase inhibitor with IC50 of 33.8 nM, as well as inhibits several cell cycle regulating kinases. ASK1-IN-3 has strong HepG2 cancer cells apoptosis induction and potent cell cycle arrest activities .
    ASK1-IN-3
  • HY-N0316R
    Mollugin (Standard)

    		JAK Reference Standards NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
    Mollugin (Standard)
  • HY-175176
    HDAC1/6-IN-3

    		HDAC Apoptosis Pyroptosis Reactive Oxygen Species (ROS) Caspase Cancer
    HDAC1/6-IN-3 is a potent HDAC inhibitor. HDAC1/6-IN-3 shows excellent inhibitory activities against HDAC1 (IC50 = 1.1 nM) and HDAC6 (IC50 = 2.7 nM). HDAC1/6-IN-3 significantly arrests HepG2 cells at the G0/G1 phase and induces apoptosis and pyroptosis. HDAC1/6-IN-3 exhibits significant antitumor activity in the HepG2 xenograft mode. HDAC1/6-IN-3 can be used for the study of cancers such as liver cancer, lung cancer, colon cancer and breast cancer .
    HDAC1/6-IN-3
  • HY-174424
    NPH16

    		PD-1/PD-L1 Apoptosis Cancer
    NPH16 is an orally active PD-1/PD-L1 inhibitor with an IC50 of 24.4 nM. NPH16 can promote HepG2 cell apoptosis. NPH16 shows excellent in vivo antitumor efficacy and favorable pharmacokinetic properties. NPH16 can be used for the study of liver cancer .
    NPH16
  • HY-N9778
    Phoyunbene B

    		Apoptosis Bcl-2 Family Caspase Drug Derivative Cancer
    Phoyunbene B is a similar substance to Resveratrol (HY-16561). Phoyunbene B exhibits stronger growth inhibitory activity against human liver cancer cells HepG2 compared to Resveratrol. Phoyunbene B induces G2/M phase cell cycle arrest and apoptosis. Phoyunbene B increases Bax/Bcl-2 and activates Caspase-3. Phoyunbene B inhibits the invasion and migration of cancer cells. Phoyunbene B can be used for research on liver cancer .
    Phoyunbene B
  • HY-N15577
    Antiproliferative agent-69

    		Drug Derivative Cancer
    Antiproliferative agent-69 (Compound 1) is a prenylated kaempferol derivative found in the fresh bud’s fur of Platanus acerifolia. Antiproliferative agent-69 shows significant antiproliferative effects against human breast cancer cells (MCF-7) and human hepatocellular carcinoma cells (Hep-G2) with IC50 values of 38.2 μM and 39.5 μM, respectively. Antiproliferative agent-69 is promising for research of breast cancer and liver cancer .
    Antiproliferative agent-69
  • HY-178133
    Pim-1 kinase-IN-14

    		Pim Apoptosis Caspase Cancer
    Pim-1 kinase-IN-14 is a PIM-1 kinase inhibitor with an IC50 value of 94 nM. Pim-1 kinase-IN-14 shows broad-spectrum and high-efficiency anticancer activity against multiple human cancer cell lines, including liver cancer (HepG-2), colon cancer (Caco-2), myeloid leukemia (NFS-60), and prostate cancer (PC-3) cells. Pim-1 kinase-IN-14exerts its anticancer effects by inducing apoptosis and activating caspase 3/7. Pim-1 kinase-IN-14 can be used for the study of cancers associated with PIM-1 kinase overexpression .
    Pim-1 kinase-IN-14
  • HY-178947
    ZINC13000658

    		METTL3 Apoptosis Cancer
    ZINC13000658 is a METTL inhibitor. ZINC13000658 exhibits significant anti proliferative activity in various cells and can induce G1 phase cell cycle arrest and apoptosis such as HepG2 (IC50 = 5.632 µM) and SNU-449 (IC50 = 6.184 µM) cells. ZINC13000658 may be related to the inhibition of the activity of multiple methyltransferases such as METTL1, 3, 6, 16, 18, etc. ZINC13000658 can be used for research on various types of cancer .
    ZINC13000658
  • HY-157404
    Pim-1/2 kinase inhibitor 2

    		Pim Cancer
    Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive PIM-1 and PIM-2 kinase inhibitor with IC50s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines .
    Pim-1/2 kinase inhibitor 2
  • HY-B0144S
    Pitavastatin-d4 hemicalcium

    NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium

    		 Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis Metabolic Disease Cancer
    Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
    Pitavastatin-d4 hemicalcium
  • HY-178960
    Tubulin-IN-59

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin-IN-59 (Compound 8g) is an orally active Tubulin inhibitor. Tubulin-IN-59 exhibits potent anti-proliferative activity against HCT116 colorectal cancer, HeLa cervical cancer, and HepG2 liver cancer cell lines, with its IC₅₀ value ranging from 16 to 35 nM. Tubulin-IN-59 arrests HeLa cells in the G2/M phase and induces cell apoptosis. Tubulin-IN-59 demonstrates significant anti-tumor activity in the HT29 human colon cancer mouse xenograft model. Tubulin-IN-59 can be used for the study of colorectal cancer and cervical cancer .
    Tubulin-IN-59
  • HY-N0882
    Desacetylcinobufotalin

    Deacetylcinobufotalin

    		 Apoptosis Bcl-2 Family Inflammation/Immunology Cancer
    Desacetylcinobufotalin is an active component isolated from Venenum Bufonis, which exhibits significant cytotoxicity against human hepatocellular carcinoma HepG2 cells (IC50 = 0.0279 µmol/mL). Desacetylcinobufotalin upregulates Bax protein expression, downregulates Bcl-2 protein expression, and induces apoptosis via the mitochondrial pathway. Desacetylcinobufotalin inhibits cancer cell survival, and shows lower cytotoxicity compared to its parent compound Cinobufagin (HY-N0421). Desacetylcinobufotalin can be used in hepatocellular carcinoma-related research .
    Desacetylcinobufotalin
  • HY-W587938
    γ-Eudesmol

    (+)-γ-Eudesmol

    		 Apoptosis Cancer
    γ-Eudesmol ((+)-γ-Eudesmol) is a mitochondrial-mediated apoptosis inducer. γ-Eudesmol binds mitochondrial membrane proteins, triggering depolarization of mitochondrial membrane potential and activating caspase cascades. γ-Eudesmol demonstrates cytotoxicity against multiple tumor cell lines (e.g., HepG2, B16-F10) with IC50 values ranging from 8.86-15.15 μg/mL. γ-Eudesmol is promising for research of cancers, such as hepatocellular carcinoma and melanoma .
    γ-Eudesmol
  • HY-N10952
    Epicornuin F

    		Others Cancer
    Epicornuin F is a prenylated flavonoid. Epicornuin F can be isolated from the leaves of Epimedium brevicornu. Epicornuin F has the cytotoxic activity against HepG2 cells with an IC50 value of 33.4 μM. Epicornuin F can be used for the research of cancer .
    Epicornuin F
  • HY-160059
    JHIT2e aptamer sodium

    		Fluorescent Dye Cancer
    JHIT2e aptamer sodium is a molecular probe based on the aptamer JHIT2 of human liver cancer cell line HepG2 cells. JHIT2e aptamer sodiu retains the ability to specifically bind HepG2 and can deliver fluorescent materials or radionuclides to tumors .
    JHIT2e aptamer sodium
  • HY-147853
    B-Raf IN 8

    		Raf Cancer
    B-Raf IN 8 (compound 7g) is a potent B-Raf inhibitor, with an IC50 of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC50 values of 9.78, 13.78, 18.52 and 29.85 µM .
    B-Raf IN 8
  • HY-N0069R
    Solamargine (Standard)

    Solamargin (Standard); δ-Solanigrine (Standard)

    		 P-glycoprotein Reference Standards Apoptosis Cancer
    Solamargine (Standard) is the analytical standard of Solamargine. This product is intended for research and analytical applications. Solamargine, a derivative from the steroidal solasodine in Solanum species, exhibits anticancer activities in numerous types of cancer. Solamargine induces non-selective cytotoxicity and P-glycoprotein inhibition. Solamargine significantly inhibits migration and invasion of HepG2 cells by down-regulating MMP-2 and MMP-9 expression and activity .
    Solamargine (Standard)
  • HY-172890
    Apoptosis inducer 37

    		Apoptosis Cancer
    Apoptosis inducer 37 (Derivative 10) is an apoptosis inducer. Apoptosis inducer 37 exerts anticancer effects by inducing S-G2/M cell cycle arrest and promoting cell apoptosis. Apoptosis inducer 37 has significant inhibitory activity against HCT116, SKOV3 and HepG2 cancer cells (IC50 values are 24.98 μM, 26.15 μM and 23.09 μM, respectively). Apoptosis inducer 37 has antitumor effects and can be used in ovarian cancer research .
    Apoptosis inducer 37
  • HY-147852
    B-Raf IN 7

    		Raf Cancer
    B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC50 of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC50 values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM .
    B-Raf IN 7
  • HY-175174
    Antiproliferative agent-73

    		Glutaminase Cancer
    Antiproliferative agent-73 (Compound 7) is an antiproliferative agent. Antiproliferative agent-73 significantly inhibits proliferation of human cancer cells with excellent cytotoxicity. Antiproliferative agent-73 has potent anticancer activity with IC50s of 15.20, 18.18, 20.20 and 13.23  μM for HepG2, MCF-7, HCT-116 and WI38 cells, respectively. Antiproliferative agent-73 can be used for cancers research, such as breast, colorectal and liver cancer .
    Antiproliferative agent-73
  • HY-163125
    BHEPN

    		VEGFR Cancer
    BHEPN is an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). BHEPN has inhibition of VEGFR-2 with an IC50 value of 0.320 μM. BHEPN also exhibits remarkable cytotoxic effects against HepG2 and MCF-7 cancer cell lines, with IC50 values of 0.19 μM and 1.18 μM, respectively. BHEPN can be used for anticancer research .
    BHEPN
  • HY-155177
    CDK9-IN-27

    		CDK Cancer
    CDK9-IN-27 (Compound 6a) is a CDK9 inhibitor (IC50s: 0.424 μM). CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC50s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research .
    CDK9-IN-27
  • HY-175565
    Tubulin/VEGFR-2-IN-1

    		Microtubule/Tubulin VEGFR Reactive Oxygen Species (ROS) Apoptosis Cancer
    Tubulin/VEGFR-2-IN-1 is a dual inhibitor of tubulin and VEGFR-2 (IC50 = 1.52 μM) with anti-angiogenic activity. Tubulin/VEGFR-2-IN-1 exhibits potent cytotoxicity against the cancer cells. Tubulin/VEGFR-2-IN-1 elevates ROS production, induces apoptosis and causes G0/G1 phase arrest in HepG-2 cells. Tubulin/VEGFR-2-IN-1 inhibits the migratory ability and the clonogenic ability in HepG-2 cells. Tubulin/VEGFR-2-IN-1 can be used for the study of cancer .
    Tubulin/VEGFR-2-IN-1
  • HY-168067
    CDK-IN-14

    		CDK Caspase Apoptosis Cancer
    CDK-IN-14 (B34) is a CDK2 inhibitor (IC50=0.097 μM) with anti-hepatocellular carcinoma activity. CDK-IN-14 blocks the cell cycle of HepG-2 cancer cells through a caspase-mediated mechanism and induces apoptosis .
    CDK-IN-14
  • HY-172225
    [Ru(phen)2(HMPIP)](PF6)2

    		Apoptosis Autophagy Ferroptosis Cancer
    [Ru(phen)2(HMPIP)](PF6)2 (Compound 6A) is an anti-tumor agent. [Ru(phen)2(HMPIP)](PF6)2 can inhibit the proliferation and migration of HepG2 liver cancer cells, and induce apoptosis, autophagy, cell cycle arrest and ferroptosis of HepG2 liver cancer cells. [Ru(phen)2(HMPIP)](PF6)2 exerts its anti-tumor activity by stimulating immune response to increase CD8+ T cells .
    [Ru(phen)2(HMPIP)](PF6)2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: